Search

Your search keyword '"Rocci, Alberto"' showing total 259 results
Start Over Author "Rocci, Alberto"
259 results on '"Rocci, Alberto"'

1. POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Author

Richardson, Paul G., primary, Badelita, Sorina N., additional, Besemer, Britta, additional, Boudreault, Jean-Samuel, additional, Byun, Ja Min, additional, Cerchione, Claudio, additional, Gatt, Moshe E., additional, Gibbs, Simon, additional, Koroda, Junya, additional, Martinez-Lopez, Joaquín, additional, Min, Chang-Ki, additional, Orlowski, Robert Z., additional, Quach, Hang, additional, Raab, Marc S., additional, Weisel, Katja, additional, Zhou, Xin, additional, Amatangelo, Michael, additional, Wang, Yue, additional, Hwang, Soo Jeong, additional, Emerson, Joshua, additional, Koo, Phillip, additional, Rocci, Alberto, additional, and Katz, Jessica, additional

Published
2023
Full Text
View/download PDF

2. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Author

Richardson, Paul G., primary, Badelita, Sorina N., additional, Besemer, Britta, additional, Boudreault, Jean-Samuel, additional, Byun, Ja Min, additional, Cerchione, Claudio, additional, Gatt, Moshe E., additional, Gibbs, Simon, additional, Koroda, Junya, additional, Martinez-Lopez, Joaquín, additional, Min, Chang-Ki, additional, Orlowski, Robert Z., additional, Quach, Hang, additional, Raab, Marc S., additional, Weisel, Katja, additional, Zhou, Xin, additional, Amatangelo, Michael, additional, Wang, Yue, additional, Hwang, Soo Jeong, additional, Emerson, Joshua, additional, Koo, Phillip, additional, Rocci, Alberto, additional, and Katz, Jessica, additional

Published
2023
Full Text
View/download PDF

3. RWD-derived response in multiple myeloma

Author

Xu, Tao, primary, Roose, James, additional, Williamson, Mellissa, additional, Sawas, Ahmed, additional, Hong, Wan-Jen, additional, Jin, Huan, additional, Maignan, Kathleen, additional, Rocci, Alberto, additional, Yousefi, Kasra, additional, Kumar, Shaji, additional, and Tyanova, Stefka, additional

Published
2023
Full Text
View/download PDF

4. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Author

Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, Labotka, Richard, Palumbo, Antonio, and Anderson, Kenneth C.

Published
2020
Full Text
View/download PDF

5. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Author

Harshman, Sean W., Canella, Alessandro, Ciarlariello, Paul D., Agarwal, Kitty, Branson, Owen E., Rocci, Alberto, Cordero, Hector, Phelps, Mitch A., Hade, Erinn M., Dubovsky, Jason A., Palumbo, Antonio, Rosko, Ashley, Byrd, John C., Hofmeister, Craig C., Benson, Don M., Jr., Paulaitis, Michael E., Freitas, Michael A., and Pichiorri, Flavia

Published
2016
Full Text
View/download PDF

6. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Author

Jackson, Graham H., Pawlyn, Charlotte, Cairns, David A., de Tute, Ruth M., Hockaday, Anna, Collett, Corinne, Jones, John R., Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A., Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Drayson, Mark T., Gregory, Walter M., Kaiser, Martin F., Owen, Roger G., Davies, Faith E., and Morgan, Gareth J.

Subjects
Cyclophosphamide -- Dosage and administration, Dexamethasone -- Dosage and administration, Multiple myeloma -- Drug therapy, Chemotherapy -- Methods, Carfilzomib -- Dosage and administration, Cancer -- Chemotherapy, Biological sciences
Abstract

Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amenable to combination therapy. Methods and findings The Myeloma XI+ trial recruited patients from 88 sites across the UK between 5 December 2013 and 20 April 2016. Patients with newly diagnosed multiple myeloma eligible for transplantation were randomly assigned to receive the combination carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) or a triplet of lenalidomide, dexamethasone, and cyclophosphamide (Rdc) or thalidomide, dexamethasone, and cyclophosphamide (Tdc). All patients were planned to receive an autologous stem cell transplantation (ASCT) prior to a randomisation between lenalidomide maintenance and observation. Eligible patients were aged over 18 years and had symptomatic myeloma. The co-primary endpoints for the study were progression-free survival (PFS) and overall survival (OS) for KRdc versus the Tdc/Rdc control group by intention to treat. PFS, response, and safety outcomes are reported following a planned interim analysis. The trial is registered (ISRCTN49407852) and has completed recruitment. In total, 1,056 patients (median age 61 years, range 33 to 75, 39.1% female) underwent induction randomisation to KRdc (n = 526) or control (Tdc/Rdc, n = 530). After a median follow-up of 34.5 months, KRdc was associated with a significantly longer PFS than the triplet control group (hazard ratio 0.63, 95% CI 0.51-0.76). The median PFS for patients receiving KRdc is not yet estimable, versus 36.2 months for the triplet control group (p < 0.001). Improved PFS was consistent across subgroups of patients including those with genetically high-risk disease. At the end of induction, the percentage of patients achieving at least a very good partial response was 82.3% in the KRdc group versus 58.9% in the control group (odds ratio 4.35, 95% CI 3.19-5.94, p < 0.001). Minimal residual disease negativity (cutoff 4 x 10.sup.-5 bone marrow leucocytes) was achieved in 55% of patients tested in the KRdc group at the end of induction, increasing to 75% of those tested after ASCT. The most common adverse events were haematological, with a low incidence of cardiac events. The trial continues to follow up patients to the co-primary endpoint of OS and for planned long-term follow-up analysis. Limitations of the study include a lack of blinding to treatment regimen and that the triplet control regimen did not include a proteasome inhibitor for all patients, which would be considered a current standard of care in many parts of the world. Conclusions The KRdc combination was well tolerated and was associated with both an increased percentage of patients achieving at least a very good partial response and a significant PFS benefit compared to immunomodulatory-agent-based triplet therapy. Trial registration ClinicalTrials.gov ISRCTN49407852., Author(s): Graham H. Jackson 1,*, Charlotte Pawlyn 2,3, David A. Cairns 4, Ruth M. de Tute 5, Anna Hockaday 4, Corinne Collett 4, John R. Jones 6, Bhuvan Kishore 7, [...]

Published
2021
Full Text
View/download PDF

7. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

Author

Pichiorri, Flavia, primary, Suh, Sung-Suk, additional, Rocci, Alberto, additional, De Luca, Luciana, additional, Taccioli, Cristian, additional, Santhanam, Ramasamy, additional, Zhou, Wenchao, additional, Benson, Don M., additional, Hofmainster, Craig, additional, Alder, Hansjuerg, additional, Garofalo, Michela, additional, Di Leva, Gianpiero, additional, Volinia, Stefano, additional, Lin, Huey-Jen, additional, Perrotti, Danilo, additional, Kuehl, Michael, additional, Aqeilan, Rami I., additional, Palumbo, Antonio, additional, and Croce, Carlo M., additional

Published
2022
Full Text
View/download PDF

11. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Author

Rocci, Alberto, Gambella, Manuela, Aschero, Simona, Baldi, Ileana, Trusolino, Livio, Cavallo, Federica, Gay, Francesca, Larocca, Alessandra, Magarotto, Valeria, Omedè, Paola, Isaia, Gianluca, Bertotti, Andrea, Liberati, Anna M., Catalano, Lucio, De Rosa, Luca, Musto, Pellegrino, Vallone, Roberto, Falcone, Antonietta, Drandi, Daniela, Ladetto, Marco, Comoglio, Paolo M., Boccadoro, Mario, and Palumbo, Antonio

Published
2014
Full Text
View/download PDF

12. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Author

Dimopoulos, Meletios A. Jakubowiak, Andrzej J. McCarthy, Philip L. Orlowski, Robert Z. Attal, Michel Blade, Joan and Goldschmidt, Hartmut Weisel, Katja C. Ramasamy, Karthik and Zweegman, Sonja Spencer, Andrew Huang, Jeffrey S. Y. Lu, Jin and Sunami, Kazutaka Iida, Shinsuke Chng, Wee-Joo Holstein, Sarah A. Rocci, Alberto Skacel, Tomas Labotka, Richard and Palumbo, Antonio Anderson, Kenneth C.

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approaches. Potential benefits of long-term strategies include sustained control of disease symptoms, as well as continued cytoreduction and clonal control, leading to unmeasurable residual disease and the possibility of transforming MM into a chronic or functionally curable condition. “Continuous therapy” commonly refers to administering a doublet or triplet regimen until disease progression, whereas maintenance approaches typically involve single-agent or doublet treatment following more intensive prior therapy with autologous stem cell transplant (ASCT) or doublet, triplet, or even quadruplet induction therapy. However, the requirements for agents and regimens within these contexts are similar: treatments must be tolerable for a prolonged period of time, should not be associated with cumulative or chronic toxicity, should not adversely affect patients’ quality of life, should ideally be convenient with a minimal treatment burden for patients, and should not impact the feasibility or efficacy of subsequent treatment at relapse. Multiple agents have been and are being investigated as long-term options in the treatment of newly diagnosed MM (NDMM), including the immunomodulatory drugs lenalidomide and thalidomide, the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, and the monoclonal antibodies daratumumab, elotuzumab, and isatuximab. Here we review the latest results with long-term therapy approaches in three different settings in NDMM: (1) maintenance treatment post ASCT; (2) continuous frontline therapy in nontransplant patients; (3) maintenance treatment post-frontline therapy in the nontransplant setting. We also discuss evidence from key phase 3 trials. Our review demonstrates how the paradigm of long-term treatment is increasingly well-established across NDMM treatment settings, potentially resulting in further improvements in patient outcomes, and highlights key clinical issues that will need to be addressed in order to provide optimal benefit.

Published
2020

17. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages

Author

Khalife, Jihane, primary, Ghose, Jayeeta, additional, Martella, Marianna, additional, Viola, Domenico, additional, Rocci, Alberto, additional, Troadec, Estelle, additional, Terrazas, Cesar, additional, Satoskar, Abhay R., additional, Gunes, Emine Gulsen, additional, Dona, Ada, additional, Sanchez, James F., additional, Bergsagel, P. Leif, additional, Chesi, Marta, additional, Pozhitkov, Alex, additional, Rosen, Steven, additional, Marcucci, Guido, additional, Keats, Jonathan J., additional, Hofmeister, Craig C., additional, Krishnan, Amrita, additional, Caserta, Enrico, additional, and Pichiorri, Flavia, additional

Published
2019
Full Text
View/download PDF

18. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome

Author

Ladetto, Marco, Vallet, Sonia, Trojan, Andreas, Dell'Aquila, Maria, Monitillo, Luigia, Rosato, Rosalba, Santo, Loredana, Drandi, Daniela, Bertola, Alessandra, Falco, Patrizia, Cavallo, Federica, Ricca, Irene, De Marco, Federica, Mantoan, Barbara, Bode-Lesniewska, Beata, Pagliano, Gloria, Francese, Roberto, Rocci, Alberto, Astolfi, Monica, Compagno, Mara, Mariani, Sara, Godio, Laura, Marino, Lydia, Ruggeri, Marina, Omedè, Paola, Palumbo, Antonio, and Boccadoro, Mario

Published
2005
Full Text
View/download PDF

20. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Author

Bastidas, Adriana de la Serna, Javier El Idrissi, Mohamed and Oostvogels, Lidia Quittet, Philippe Lopez-Jimenez, Javier and Vural, Filiz Pohlreich, David Zuckerman, Tsila Issa, Nicolas C. Gaidano, Gianluca Lee, Je-Jung Abhyankar, Sunil and Solano, Carlos Perez de Oteyza, Jaime Satlin, Michael J. and Schwartz, Stefan Campins, Magda Rocci, Alberto Llamas, Carlos Vallejo Lee, Dong-Gun Tan, Sen Mui Johnston, Anna M. and Grigg, Andrew Boeckh, Michael J. Campora, Laura and Lopez-Fauqued, Marta Heineman, Thomas C. Stadtmauer, Edward A. and Sullivan, Keith M. Alonso Alonso, Aranzazu Anagnostopoulos, Achilles Andreadis, Charalambos (Babis) Angelopoulou, Maria and Anttila, Veli-Jukka Aoun, Mickael Barista, Ibrahim Berkahn, Leanne Bloor, Adrian J. C. Broady, Raewyn Brossart, Peter and Buadi, Francis K. Bulabois, Claude-Eric Cantin, Guy and Cellini, Claudia Chandrasekar, Pranatharthi Haran Chauncey, Thomas Cuneo, Antonio Dadwal, Sanjeet Singh Dickinson, Michael Eom, HyeonSeok Esquirol Sanfeliu, Albert Ferra Coll, Christelle Flomenberg, Phyllis R. Pilar Gonzalez-Rodriguez, Ana and Gottlieb, David J. Grisariu, Sigal Guenther, Andreas and Gutman, Jonathan Hahn, Uwe Heinz, Werner J. Heras, Inmaculada Ikeda, Takashi Jarque, Isidro Karthaus, Meinolf and Kerre, Tessa Kiani, Alexander Klein, Andreas K. Kofla, Grzegorz Kryuchkova, Irina V. Kuo, Ching-Yuan Kuruvilla, John Kuvshinov, Aleksey Kwak, Jae-Yong Lee, Jae Hoon and Lepretre, Stephane Lie, Albert Kwok-Wai Lucchesi, Alessandro and Maertens, Johan Marijt, Erik W. A. Martinez Munoz, Carmen and Michieli, Mariagrazia Milliken, Samuel T. Milpied, Noel and Monserrat Coll, Jorge Mossad, Sherif Beniameen Murphy, John and Navarro Matilla, Maria Belen Novak, Jan Olney, Harold J. Ona Navarrete, Raquel Pascual Cascon, Maria Jesus Peniket, Andy and Penka, Ganeva Piatkowska-Jakubas, Beata Polo Zarzuela, Marta and Quiel, Dimas Rowley, Scott D. Sabry, Waleed Salmi, Tommi Mikael Selleslag, Dominik L. D. Shea, Thomas C. Silling, Gerda Sinisalo, Ulla Marjatta Sohn, Sang Kyun Staib, Peter and Szer, Jeff Theunissen, Koen Topcuoglu, Pervin Tyurina, Natalya G. Uvarov, Mikhail Wahid, Fadilah S. Abdul Yanez San Segundo, Lucrecia Yegin, Zeynep Arzu Yeh, Su-Peng Yip, Sze-Fai Yoon, Sung Soo Young, Jo-Anne H. Zachee, Pierre and Zaja, Francesco ZOE-HSCT Study Grp Collaborators

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P

Published
2019

21. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

Author

Bonanno Giuseppina, Mariotti Andrea, Procoli Annabella, Folgiero Valentina, Natale Daniela, De Rosa Luca, Majolino Ignazio, Novarese Linda, Rocci Alberto, Gambella Manuela, Ciciarello Marilena, Scambia Giovanni, Palumbo Antonio, Locatelli Franco, De Cristofaro Raimondo, and Rutella Sergio

Subjects
Medicine
Abstract

Abstract Background Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and promote regulatory T-cell (Treg) differentiation. It is presently unknown whether MM cells express IDO1 and whether IDO1 activity correlates with immune system impairment. Methods We investigated IDO1 expression in 25 consecutive patients with symptomatic MM and in 7 patients with either monoclonal gammopathy of unknown significance (MGUS; n=3) or smoldering MM (SMM; n=4). IDO1-driven tryptophan breakdown was correlated with the release of hepatocyte growth factor (HGF) and with the frequency of Treg cells and NY-ESO-1-specific CD8+ T cells. Results KYN was increased in 75% of patients with symptomatic MM and correlated with the expansion of CD4+CD25+FoxP3+ Treg cells and the contraction of NY-ESO-1-specific CD8+ T cells. In vitro, primary MM cells promoted the differentiation of allogeneic CD4+ T cells into bona fide CD4+CD25hiFoxP3hi Treg cells and suppressed IFN-γ/IL-2 secretion, while preserving IL-4 and IL-10 production. Both Treg expansion and inhibition of Th1 differentiation by MM cells were reverted, at least in part, by d,l-1-methyl-tryptophan, a chemical inhibitor of IDO. Notably, HGF levels were higher within the BM microenvironment of patients with IDO+ myeloma disease compared with patients having IDO- MM. Mechanistically, the antagonism of MET receptor for HGF with SU11274, a MET inhibitor, prevented HGF-induced AKT phosphorylation in MM cells and translated into reduced IDO protein levels and functional activity. Conclusions These data suggest that IDO1 expression may contribute to immune suppression in patients with MM and possibly other HGF-producing cancers.

Published
2012
Full Text
View/download PDF

23. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Author

Gambella, Manuela, primary, Omedé, Paola, additional, Spada, Stefano, additional, Muccio, Vittorio Emanuele, additional, Gilestro, Milena, additional, Saraci, Elona, additional, Grammatico, Sara, additional, Larocca, Alessandra, additional, Conticello, Concetta, additional, Bernardini, Annalisa, additional, Gamberi, Barbara, additional, Troia, Rossella, additional, Liberati, Anna Marina, additional, Offidani, Massimo, additional, Rocci, Alberto, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Oliva, Stefania, additional

Published
2018
Full Text
View/download PDF

25. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors

Author

Tornatore Laura, Sandomenico Annamaria, Raimondo Domenico, Low Caroline, Rocci Alberto, Tralau-Stewart Cathy, Capece Daria, D'Andrea Daniel, Bua Marco, Boyle Eileen, van Duin Mark, Zoppoli Pietro, Jaxa-Chamiec Albert, Thotakura Anil K, Dyson Julian, Walker Brian A, Leonardi Antonio, Chambery Angela, Driessen Christoph, Sonneveld Pieter, Morgan Gareth, Palumbo Antonio, Tramontano Anna, Rahemtulla Amin, and Ruvo Menotti

Abstract

Constitutive NF ?B signaling promotes survival in multiple myeloma (MM) and other cancers; however current NF ?B targeting strategies lack cancer cell specificity. Here we identify the interaction between the NF ?B regulated antiapoptotic factor GADD45ß and the JNK kinase MKK7 as a therapeutic target in MM. Using a drug discovery strategy we developed DTP3 a D tripeptide which disrupts the GADD45ß/MKK7 complex kills MM cells effectively and importantly lacks toxicity to normal cells. DTP3 has similar anticancer potency to the clinical standard bortezomib but more than 100 fold higher cancer cell specificity in vitro. Notably DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. Hence cancer selective targeting of the NF ?B pathway is possible and at least for myeloma patients promises a profound benefit.

Published
2014
Full Text
View/download PDF

26. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Author

Ross, Fiona M, Avet-Loiseau, Hervé, Ameye, Geneviève, Gutiérrez, Norma C, Liebisch, Peter, O'Connor, Sheila, Dalva, Klara, Fabris, Sonia, Testi, Adele M, Jarosova, Marie, Hodkinson, Clare, Collin, Anna, Kerndrup, Gitte, Kuglik, Petr, Ladon, Dariusz, Bernasconi, Paolo, Maes, Brigitte, Zemanova, Zuzana, Michalova, Kyra, Michaux, Lucienne, Neben, Kai, Hermansen, N Emil U, Rack, Katrina, Rocci, Alberto, Protheroe, Rebecca, Chiecchio, Laura, Poirel, Hélène, Sonneveld, Pieter, Nyegaard, Mette, Johnsen, Hans E, the European Myeloma Network, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (SLuc) Service d'hématologie, and Hematology

Subjects
medicine.medical_specialty, MEDLINE, Bioinformatics, 03 medical and health sciences, Prospective analysis, 0302 clinical medicine, Clinical report, Internal medicine, medicine, Humans, In Situ Hybridization, Fluorescence, Multiple myeloma, 030304 developmental biology, 0303 health sciences, Hematology, medicine.diagnostic_test, business.industry, Network on, medicine.disease, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, %22">Fish , Original Articles and Brief Reports, Multiple Myeloma, business, Fluorescence in situ hybridization
Abstract

The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analysed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise there was acceptable agreement on more than 1000 tests. The conclusions from the collaboration were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) Material should be part of the first draw of the aspirate; 2) Samples should be sent at suitable times that allow for the lengthy processing; 3) Most importantly PCs must be purified or specifically identified; 4) Positive cut-off levels should be the relatively conservative, 10% for fusion or break-apart probes and 20% for numerical abnormalities; 5) Informative probes should be combined to best effect; 6) In specialist laboratories a single experienced analyst is considered adequate; 7) At least 100 PC should be scored; 8) Essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) Suitable commercial probes are available for clinically relevant abnormalities; 10) The clinical report should be expressed clearly and must state the percentage of PC involved and method used for identification; 11) A retrospective European based FISH data bank linked to clinical data should be generated and 12) Prospective analysis should be centralized for upcoming trials based on the recommendations. EMN aims to build on these recommendations to establish standards for a common European database to define subgroups with prognostic significance. ispartof: Haematologica vol:97 issue:8 pages:1272-1277 ispartof: location:Italy status: published

Published
2012

28. High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma

Author

Bolomsky, Arnold, primary, Hübl, Wolfgang, additional, Spada, Stefano, additional, Müldür, Ercan, additional, Schlangen, Karin, additional, Heintel, Daniel, additional, Rocci, Alberto, additional, Weißmann, Adalbert, additional, Fritz, Veronique, additional, Wilheim, Martin, additional, Zojer, Niklas, additional, Palumbo, Antonio, additional, and Ludwig, Heinz, additional

Published
2017
Full Text
View/download PDF

29. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Author

Pichiorri, Flavia, primary, Palmieri, Dario, additional, De Luca, Luciana, additional, Consiglio, Jessica, additional, You, Jia, additional, Rocci, Alberto, additional, Talabere, Tiffany, additional, Piovan, Claudia, additional, Lagana, Alessandro, additional, Cascione, Luciano, additional, Guan, Jingwen, additional, Gasparini, Pierluigi, additional, Balatti, Veronica, additional, Nuovo, Gerard, additional, Coppola, Vincenzo, additional, Hofmeister, Craig C., additional, Marcucci, Guido, additional, Byrd, John C., additional, Volinia, Stefano, additional, Shapiro, Charles L., additional, Freitas, Michael A., additional, and Croce, Carlo M., additional

Published
2017
Full Text
View/download PDF

30. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Gay, Francesca, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Passera, Roberto, additional, Pautasso, Chiara, additional, Bernardini, Annalisa, additional, Genuardi, Mariella, additional, Patriarca, Francesca, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Conticello, Concetta, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2016
Full Text
View/download PDF

31. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Author

Bastidas, Adriana, de la Serna, Javier, El Idrissi, Mohamed, Oostvogels, Lidia, Quittet, Philippe, López-Jiménez, Javier, Vural, Filiz, Pohlreich, David, Zuckerman, Tsila, Issa, Nicolas C., Gaidano, Gianluca, Lee, Je-Jung, Abhyankar, Sunil, Solano, Carlos, Perez de Oteyza, Jaime, Satlin, Michael J., Schwartz, Stefan, Campins, Magda, Rocci, Alberto, and Vallejo Llamas, Carlos

Subjects
HERPES zoster vaccines, HERPES zoster, HEMATOPOIETIC stem cell transplantation, RECOMBINANT drugs, CLINICAL trials, HERPES zoster prevention, RESEARCH, IMMUNOCOMPROMISED patients, NEURALGIA, RESEARCH methodology, DISEASE incidence, IMMUNOMODULATORS, EVALUATION research, MEDICAL cooperation, INTRAMUSCULAR injections, AUTOGRAFTS, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, HOSPITAL care, PROPORTIONAL hazards models, LONGITUDINAL method
Abstract

Importance: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.Objective: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients.Design, Setting, and Participants: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT.Interventions: Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter.Main Outcomes and Measures: The primary end point was occurrence of confirmed herpes zoster cases.Results: Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P = .02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P = .02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P = .01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points.Conclusions and Relevance: Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months.Trial Registration: ClinicalTrials.gov Identifier: NCT01610414. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

32. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Author

Gambella, Manuela, Omedé, Paola, Spada, Stefano, Muccio, Vittorio Emanuele, Gilestro, Milena, Saraci, Elona, Grammatico, Sara, Larocca, Alessandra, Conticello, Concetta, Bernardini, Annalisa, Gamberi, Barbara, Troia, Rossella, Liberati, Anna Marina, Offidani, Massimo, Rocci, Alberto, Palumbo, Antonio, Cavo, Michele, Sonneveld, Pieter, Boccadoro, Mario, and Oliva, Stefania

Subjects
POLYMERASE chain reaction, REVERSE transcriptase polymerase chain reaction, FLOW cytometry, OLIGONUCLEOTIDE synthesis, ONCOLOGY, MULTIPLE myeloma, PROGRESSION-free survival
Abstract

Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis.Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10-5 ) and MFC (sensitivity, from 10-4 to 10-5 ).Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P = .0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P < .001). The impact of negative MRD status on PFS was similar in all subgroups (ASCT and no-ASCT; International Staging System stages I, II, and III; high-risk and standard-risk cytogenetics), and the two techniques were highly correlated.Conclusions: MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

Author

Richardson, Paul G., Amatangelo, Michael, Berenson, James R., Cerchione, Claudio, Dimopoulos, Meletios A., Toftmann Hansen, Charlotte, Hwang, Soo Jeong, Koo, Phillip, Kuroda, Junya, Oriol, Albert, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Rocci, Alberto, Wang, Yue, White, Darrell, Yu, Brian, Zhou, Zehua, and Katz, Jessica

Published
2023
Full Text
View/download PDF

34. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

Author

Gambella, Manuela, Rocci, Alberto, Passera, Roberto, Gay, Francesca, Omedè, Paola, Crippa, Claudia, Corradini, Paolo, Romano, Alessandra, Rossi, Davide, Ladetto, Marco, Boccadoro, Mario, and Palumbo, Antonio

Subjects
Male, X-Box Binding Protein 1, XBP1, Myeloma protein, Antineoplastic Agents, Regulatory Factor X Transcription Factors, Biology, Disease-Free Survival, BLIMP1, Bortezomib, IRF4, medicine, Biomarkers, Tumor, Humans, Letters to the Editor, Transcription factor, Multiple myeloma, Aged, Neoplastic, Tumor, Hematology, medicine.disease, Molecular biology, Boronic Acids, Neoplasm Proteins, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, Survival Rate, medicine.anatomical_structure, Gene Expression Regulation, multiple myeloma biomarker, Pyrazines, Monoclonal, Cancer research, Female, Bone marrow, Multiple Myeloma, Biomarkers, medicine.drug, Transcription Factors
Abstract

Multiple myeloma (MM) is a hematologic tumor characterized by accumulation of monoclonal plasma cells (PCs) in the bone marrow (BM) producing antigen-specific immunoglobulins. The transcription factor X box binding protein 1 (XBP1), the interferon regulatory factor 4 (IRF4) and the transcriptional

Published
2014

35. Cancer-Selective Targeting of the NF-kappa B Survival Pathway with GADD45 beta/MKK7 Inhibitors

Author

Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D'Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido, Tornatore, L, Sandomenico, A, Raimondo, D, Low, C, Rocci, A, Tralau-Stewart, C, Capece, D, D'Andrea, D, Bua, M, Boyle, E, van Duin, M, Zoppoli, P, Jaxa-Chamiec, A, Thotakura, Ak, Dyson, J, Walker, Ba, Leonardi, A, Chambery, A, Driessen, C, Sonneveld, P, Morgan, G, Palumbo, A, Tramontano, A, Rahemtulla, A, Ruvo, M, Franzoso, G, Pathology, Plastic and Reconstructive Surgery and Hand Surgery, Hematology, Medical Research Council (MRC), and Cancer Research UK

Subjects
EXPRESSION, BORTEZOMIB, Biological Availability, Antineoplastic Agents, Cell Cycle Proteins, MAP Kinase Kinase 7, MKK7/JNKK2, ACTIVATION, PROTEASOME INHIBITOR, INFLAMMATION, SDG 3 - Good Health and Well-being, MULTIPLE-MYELOMA, KINASE, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, mieloma multiplo, Science & Technology, NF-kappa B, Nuclear Proteins, Cell Biology, Oncology, CELLS, SIGNALING PATHWAY, Multiple Myeloma, 1109 Neurosciences, Life Sciences & Biomedicine
Abstract

Constitutive NF-B-K signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-B-K-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the NF-B-K-regulated antiapoptotic factor GADD45 beta and the JNK kinase MKK7 as a therapeutic target in MM. Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45 beta/ MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro. Notably, DTP3 ablates rnyeloma xenografts in mice with no apparent side effects at the effective doses. Hence, cancer-selective targeting of the NF-KB pathway is possible and, at least for myeloma patients, promises a profound benefit.

Published
2014

36. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

Author

Pichiorri, Flavia, primary, Suh, Sung-Suk, additional, Rocci, Alberto, additional, De Luca, Luciana, additional, Taccioli, Cristian, additional, Santhanam, Ramasamy, additional, Zhou, Wenchao, additional, Benson, Don M., additional, Hofmainster, Craig, additional, Alder, Hansjuerg, additional, Garofalo, Michela, additional, Di Leva, Gianpiero, additional, Volinia, Stefano, additional, Lin, Huey-Jen, additional, Perrotti, Danilo, additional, Kuehl, Michael, additional, Aqeilan, Rami I., additional, Palumbo, Antonio, additional, and Croce, Carlo M., additional

Published
2016
Full Text
View/download PDF

38. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Author

Radomska, Hanna, primary, Canella, Alessandro, additional, Jessica, Consiglio, additional, Rocci, Alberto, additional, Luciano, Cascione, additional, Cordero, Hector, additional, Joseph, Liu, additional, Caserta, Enrico, additional, Ramasamy, Santhanam, additional, Efebera, Yvonne A., additional, Volinia, Stefano, additional, Hofmeister, Craig C, additional, and Pichiorri, Flavia, additional

Published
2015
Full Text
View/download PDF

39. Lenalidomide for Multiple Myeloma

Author

Palumbo, Antonio Rocci, Alberto Ludwig, Heinz Dimopoulos, Meletios

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2012

41. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

Author

Engelhardt, Monika Udi, Josefina Kleber, Martina Spencer, Andrew Rocci, Alberto Knop, Stefan Bruno, Benedetto and Bringhen, Sara Perez-Simon, Jose A. Zweegman, Sonja and Driessen, Christoph Patriarca, Francesca Gramatzki, Martin and Terpos, Evangelos Sezer, Orhan Kropff, Martin Straka, Christian Johnsen, Hans E. Waage, Anders Boegsted, Martin and Lokhorst, Henk Hajek, Roman Morgan, Gareth Boccadoro, Mario Ludwig, Heinz Cavo, Michele Polliack, Aaron and Sonneveld, Pieter Einsele, Hermann Palumbo, Antonio

Abstract

Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.

Published
2010

42. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix

Author

Glavey, Siobhan, primary, Naba, Alexandra, additional, Manier, Salomon, additional, Gambella, Manuela, additional, Rocci, Alberto, additional, Sacco, Antonio, additional, Asara, John M., additional, Moschetta, Michele, additional, Reagan, Michaela R., additional, Mishima, Yuji, additional, Kawano, Yawara, additional, Roccaro, Aldo M, additional, Palumbo, Antonio, additional, Hynes, Richard O., additional, and Ghobrial, Irene M., additional

Published
2014
Full Text
View/download PDF

43. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide

Author

Gambella, Manuela, primary, Omedè, Paola, additional, Oliva, Stefania, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Gay, Francesca, additional, Patriarca, Francesca, additional, Palladino, Carmela, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Di Raimondo, Francesco, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2014
Full Text
View/download PDF

44. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

Author

Tornatore, Laura, primary, Sandomenico, Annamaria, additional, Raimondo, Domenico, additional, Low, Caroline, additional, Rocci, Alberto, additional, Tralau-Stewart, Cathy, additional, Capece, Daria, additional, D’Andrea, Daniel, additional, Bua, Marco, additional, Boyle, Eileen, additional, van Duin, Mark, additional, Zoppoli, Pietro, additional, Jaxa-Chamiec, Albert, additional, Thotakura, Anil K., additional, Dyson, Julian, additional, Walker, Brian A., additional, Leonardi, Antonio, additional, Chambery, Angela, additional, Driessen, Christoph, additional, Sonneveld, Pieter, additional, Morgan, Gareth, additional, Palumbo, Antonio, additional, Tramontano, Anna, additional, Rahemtulla, Amin, additional, Ruvo, Menotti, additional, and Franzoso, Guido, additional

Published
2014
Full Text
View/download PDF

46. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

Author

Pichiorri, Flavia, Suh, Sung-Suk, Rocci, Alberto, De Luca, Luciana, Taccioli, Cristian, Santhanam, Ramasamy, Zhou, Wenchao, Benson, Don M., Jr., Hofmainster, Craig, Alder, Hansjuerg, Garofalo, Michela, Di Leva, Gianpiero, Volinia, Stefano, Lin, Huey-Jen, Perrotti, Danilo, Kuehl, Michael, Aqeilan, Rami I., Palumbo, Antonio, and Croce, Carlo M.

Published
2010
Full Text
View/download PDF

48. Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients

Author

Rocci, Alberto, primary, Gambella, Manuela, additional, Omedè, Paola, additional, Drandi, Daniela, additional, Gay, Francesca, additional, Patriarca, Francesca, additional, Cavallo, Federica, additional, Petrucci, Maria Teresa, additional, Tommaso, Caravita, additional, Benevolo, Giulia, additional, Pescosta, Norbert, additional, Oliva, Stefania, additional, Offidani, Massimo, additional, Montefusco, Vittorio, additional, Liberati, Anna Marina, additional, Falcone, Antonietta Pia, additional, Ballanti, Stelvio, additional, Spadano, Tonino, additional, Guglielmelli, Tommasina, additional, Musto, Pellegrino, additional, Zambello, Renato, additional, Di Raimondo, Francesco, additional, Ladetto, Marco, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2013
Full Text
View/download PDF

49. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Author

Ferrero, Simone, primary, Ladetto, Marco, additional, Drandi, Daniela, additional, Cavallo, Federica, additional, Genuardi, Elisa, additional, Urbano, Marina, additional, Guarona, Guglielmo, additional, Callea, Vincenzo, additional, Cangialosi, Clotilde, additional, Caravita, Tommaso, additional, Crippa, Claudia, additional, De Rosa, Luca, additional, Falcone, Antonietta Pia, additional, Grasso, Mariella, additional, Guglielmelli, Tommasina, additional, Liberati, Anna Marina, additional, Pisani, Francesco, additional, Pregno, Patrizia, additional, Rossini, Fausto, additional, Oliva, Stefania, additional, Rocci, Alberto, additional, Passera, Roberto, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2013
Full Text
View/download PDF

50. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma

Author

Pichiorri, Flavia, primary, Rocci, Alberto, additional, Hofmeister, Craig C, additional, Geyer, Susan, additional, Talabere, Tiffany, additional, Gambella, Massimiliano, additional, Cascione, Luciano, additional, Stiff, Andrew, additional, Benson, Don M., additional, Efebera, Yvonne A, additional, Dirisala, Vijaya, additional, Smith, Emily M, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Rossi, Davide, additional, Gentili, Silvia, additional, Uccello, Giuseppina, additional, Ria, Roberto, additional, Benevolo, Giulia, additional, Bringhen, Sara, additional, Callea, Vincenzo, additional, Weiss, Brendan M, additional, Ferro, Alfredo, additional, Magarotto, Valeria, additional, Alder, Hansjuerg, additional, Byrd, John C., additional, Boccadoro, Mario, additional, Marcucci, Guido, additional, and Palumbo, Antonio, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results